Intra-articular CD1c-expressing myeloid dendritic cells from rheumatoid arthritis patients express a unique set of T cell-attracting chemokines and spontaneously induce Th1, Th17 and Th2 cell activity by Frederique M Moret et al.
Moret et al. Arthritis Research & Therapy 2013, 15:R155
http://arthritis-research.com/content/15/5/R155RESEARCH ARTICLE Open AccessIntra-articular CD1c-expressing myeloid dendritic
cells from rheumatoid arthritis patients express a
unique set of T cell-attracting chemokines and
spontaneously induce Th1, Th17 and Th2 cell
activity
Frederique M Moret1*, Cornelis E Hack2, Kim MG van der Wurff-Jacobs1, Wilco de Jager2, Timothy RDJ Radstake1,2,
Floris PJG Lafeber1 and Joel AG van Roon1,2Abstract
Introduction: Myeloid dendritic cells (mDCs) are potent T cell-activating antigen-presenting cells that have been
suggested to play a crucial role in the regulation of immune responses in many disease states, including
rheumatoid arthritis (RA). Despite this, studies that have reported on the capacity of naturally occurring circulating
mDCs to regulate T cell activation in RA are still lacking. This study aimed to evaluate the phenotypic and functional
properties of naturally occurring CD1c (BDCA-1)+ mDCs from synovial fluid (SF) compared to those from peripheral
blood (PB) of RA patients.
Methods: CD1c+mDC numbers and expression of costimulatory molecules were assessed by fluorescence-activated
cell sorting (FACS) analysis in SF and PB from RA patients. Ex vivo secretion of 45 inflammatory mediators by mDCs from
SF and PB of RA patients was determined by multiplex immunoassay. The capacity of mDCs from SF to activate
autologous CD4+ T cells was measured.
Results: CD1c+mDC numbers were significantly increased in SF versus PB of RA patients (mean 4.7% vs. 0.6%). mDCs
from SF showed increased expression of antigen-presenting (human leukocyte antigen (HLA) class II, CD1c) and
costimulatory molecules (CD80, CD86 and CD40). Numerous cytokines were equally abundantly produced by mDCs
from both PB and SF (including IL-12, IL-23, IL-13, IL-21). SF mDCs secreted higher levels of interferon γ-inducible
protein-10 (IP-10), monokine induced by interferon γ (MIG) and, thymus and activation-regulated chemokine (TARC),
but lower macrophage-derived chemokine (MDC) levels compared to mDCs from PB. mDCs from SF displayed a
strongly increased capacity to induce proliferation of CD4+ T cells associated with a strongly augmented IFNγ, IL-17,
and IL-4 production.
Conclusions: This study suggests that increased numbers of CD1c+mDCs in SF are involved in the inflammatory
cascade intra-articularly by the secretion of specific T cell-attracting chemokines and the activation of self-reactive
T cells.* Correspondence: f.m.moret@umcutrecht.nl
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Rheumatoid arthritis (RA) is an autoimmune disorder char-
acterised by persistent joint inflammation resulting in pro-
gressive destruction of the joint tissues [1]. CD4+ T cells
producing T-helper type (Th)-1 (interferon gamma
(IFNγ)) and Th17 cytokines (interleukin (IL)-17) [2-5],
as well as B cells of the adaptive immune system and
macrophages and dendritic cells (DCs) of the innate im-
mune system all contribute to joint inflammation and
immunopathology of RA.
DCs are the professional antigen-presenting cells in-
volved in the coordination of adaptive immune responses
during infections and against tumour cells. DCs instruct T
cells to develop a proper immune response by uptake and
presentation of antigens and the provision of costimulatory
signals and cytokines. In addition, DCs have the ability to
instruct T cells to induce self-tolerance by presenting self-
antigens to T cells and subsequent deletion or inactivation
of self-reactive T cells [6]. External agents to DCs such as
cytokines, tissue-derived factors, pathogen-derived antigens
and organic molecules may alter the balance between tol-
erogenic and immunogenic activity of DCs and induce
autoimmune disease [7,8].
Human blood DCs are divided into several phenotyp-
ically and functionally different subpopulations including
myeloid dendritic cells (mDCs) [9]. mDCs express
CD11c and are subdivided into three subsets, of which
CD1c+ (BDCA-1+) mDCs are the most abundant popu-
lation [10-12]. Since CD1c, apart from mDCs, is only
expressed by a subset of B cells, this marker can be used
to identify and isolate this unique subset of human
mDCs [13,14]. CD1c is a major histocompatibility com-
plex class I-like cell surface glycoprotein that presents
lipid and glycolipid self-antigens and nonself-antigens,
so CD1c+ mDCs can activate restricted lipid antigen-
specific T cells [15]. However, these mDCs also have a
strong capacity to induce a major histocompatibility
complex-dependent antigen-driven allogeneic mixed
lymphocyte reaction [11]. CD1c+ mDCs in the circula-
tion have been suggested to represent immature DCs
that express CD86 and respond to microbial products
rather than to inflammatory stimuli (such as tumour ne-
crosis factor alpha) [12]. Recently, CD1c+ mDCs were
described to have an immunoregulatory function in re-
sponse to certain microbial triggers [16,17].
Despite the fact that mDCs have been extensively
studied in immune disorders in mice and man and that
they have been suggested to play an important role in
the pathogenesis of RA [18], functional data on naturally
occurring mDCs in RA, including those expressing
CD1c, are scarce. Previous studies on mDCs in RA were
based on CD33/CD14 expression, describing a larger
mDC population than the recently defined CD1c+ mDCs
[19], since CD33 is not only expressed on CD1c+ mDCsbut also on CD16+ and BDCA-3+ DC subpopulations
[11]. Only a small percentage of CD1c+ mDCs express
CD14 and the function of these double-positive mDCs is
still unknown [20]. In RA, mDCs are increased in the
joints as compared with the circulation and express co-
stimulatory molecules [21,22]. However, a detailed ana-
lysis of the capacity of ex vivo cultured CD1c+ mDCs
from RA patients to produce inflammatory mediators
and activate T cells has not been performed.
In the present study, the function of CD1c+ mDCs (also
referred to as mDCs) from peripheral blood (PB) and
synovial fluid (SF) of RA patients was examined. The
capacity of mDCs to secrete T cell-differentiating cyto-
kines (including IL-12, IL-33, IL-23), chemokines (includ-
ing CCL17/thymus and activation-regulated chemokine
(TARC), CXCL9/monokine induced by interferon-gamma
(MIG), CXCL10/interferon-gamma inducible protein-10
(IP-10)) and proinflammatory cytokines (including IL-1β,
IL-6) was studied in combination with their capacity to
induce autologous T cell proliferation and cytokine pro-
duction (IFNγ, IL-17 and IL-4).
Methods
Patients
The patients included in this study all met the American
College of Rheumatology criteria for RA [23]. Demo-
graphic and clinical data of these patients are presented
in Table 1. SF and PB samples were collected from the
patients. Ethical approval for this study was given by the
medical ethical committee of the University Medical
Center Utrecht for the collection of patient samples in
compliance with the Helsinki Declaration. All patients
gave their informed consent.
Flow cytometry
The number and characteristics of CD1c+ mDCs present in
mononuclear cell (MNC) fractions of paired PB and SF sam-
ples of RA patients were analysed by fluorescence-activated
cell sorting (FACS) analysis using a FACS CANTO II flow
cytometer (BD Biosciences, San Jose, CA, USA). Cells were
stained for CD1c-PE (Biolegend, San Diego, CA, USA),
CD19-PERCP-Cy5.5 (BD Biosciences) and CD14 -APC (BD
Pharmingen, San Diego, CA, USA) and were identified as
CD19-negative and CD1c-positive. Cell surface marker
expression on CD1c+ mDCs was studied with the following
reagents: IgG isotype FITC/PE (Immunotech, Marseille,
France), HLA-DR/DP/DQ-FITC (BD Pharmingen), CD80-
PE, CD86-PE, CD40-PE and CD19-PERCP-Cy5.5 (all BD
Biosciences), and CD1c-Pacific Blue (Biolegend). All data
were analysed using FlowJo software (Tree Star, Ashland,
OR, USA). To compare mean fluorescence intensity (MFI)
values of human leukocyte antigen (HLA) class II, CD80,
CD86 and CD40 expression on mDCs from PB and SF, the
intensity of autofluorescence assessed using isotype controls
Table 1 Demographic and clinical characteristics of
rheumatoid arthritis patients
PB SF Paired PB + SF












16 ± 19 26 ± 22 34 ± 22
C-reactive protein
(mg/l)





Data presented as mean ± standard deviation or number. DMARD, disease-
modifying anti-rheumatic drugs; NSAID, nonsteroidal anti-inflammatory drugs;
PB, peripheral blood; SF, synovial fluid. aThree and beight missing
values, respectively.
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of the stainings to reveal true expression differences.
Cell isolation
MNCs from lithium-heparinised PB and SF were iso-
lated by density centrifugation using Ficoll-Paque Plus
(GE Healthcare, Uppsala, Sweden). Prior to MNC isola-
tion, PB or SF was diluted 1:1 with RPMI 1640 medium
(Gibco, Life Technologies, New York, USA) containing
penicillin (100 U/ml), streptomycin (100 μg/ml), and L-
glutamine (2 mM) (all PAA Laboratories, Pasching,
Austria). CD1c+ mDCs from PB and SF and CD4+ T
cells from PB were isolated from MNC fractions by
magnetic-activated cell sorting using CD1c+ (BDCA-1+)
DC and CD4+ T cell isolation kits (Miltenyi Biotec,
Bergisch Gladbach, Germany), respectively, according to
the manufacturer’s instructions.
Cell cultures
Cells were cultured in RPMI glutamax (Gibco) supplemented
with penicillin (100 U/ml), streptomycin (100 μg/ml), and
10% human AB serum (v/v; GemCell, West Sacramento,
CA, USA). Isolated CD4+ T cells were seeded in round-
bottomed 96-well plates (NUNC, Roskilde, Denmark) at a
concentration of 0.5 × 106 cells/ml and stored at 37°C
before co-culturing with mDCs. The viable mDCs were
counted and equal amounts of live cells were either cul-
tured alone or cocultured with CD4+ T cells. To measure
cytokine production, isolated mDCs from PB and SF of
RA patients were cultured at a concentration of 0.5 × 106
cells/ml for 20 hours at 37°C. Supernatants were harvested
and tested for multiple cytokines with multiplex immuno-
assay. To determine the effect of PB-derived and SF-derived mDCs (≤10,000 cells/well) on autologous CD4+ T
cells (50,000 cells/well), mDCs derived from PB or SF
were added to autologous peripheral CD4+ T cells in
triplicate at increasing DC:T cell ratios in the absence
of additional stimuli. To determine the effect of CD80/
86-dependent costimulation in SF mDC/T cell co-
cultures, cells were cultured in the presence of CTLA4-
Ig (10 μg/ml; Bristol-Myers Squibb, New York, NY,
USA). To study whether the observed differences
between PB mDCs and SF mDCs were related to mDC
maturation, as a control we activated mDCs from PB with
thymic stromal lymphopoeitin (TSLP, 20 ng/ml for 20
hours preceding coculture; R&D Systems, Minneapolis,
MN, USA). Cells were cocultured in round-bottomed 96-
well plates for 6 days and subsequently proliferation and
cytokine production were measured. Proliferation was
measured by 3H-thymidine incorporation assay at the
end of the culture period. 3H-thymidine (1 μCi/well;
PerkinElmer, Waltham, MA, USA) was added during
the last 18 hours of the culture period. T cell cytokine
production was measured in supernatants of cocultured
cells upon short-term restimulation with 500 ng/ml
ionomycin and 50 ng/ml phorbol myristate acetate
(both Sigma-Aldrich, St Louis, MO, USA) during the
last 24 hours of the culture period.
Cytokine assessment
Cytokines and chemokines in supernatants of cultured
mDCs derived from PB and SF were assessed by a mul-
tiplex immunoassay as described elsewhere [24]. The
cytokines measured and their expression levels are pre-
sented in Table 2. T cell cytokines produced by CD4+ T
cells cocultured with CD1c+ mDCs were analysed upon
restimulation with ionomycin/phorbol myristate acetate.
IFNγ, IL-4 (Invitrogen, Life Technologies, New York,
USA) and IL-17 (R&D Systems) were measured by
enzyme-linked immunosorbent assay according to the
manufacturer’s instructions.
Statistical analysis
Paired-sample evaluation was performed using the non-
parametric Wilcoxon signed-rank test. Unpaired data
analysis was performed using the nonparametric
Mann–Whitney U test. Data analysis was performed
using SPSS software (IBM, Armonk, NY, USA). Data
were considered statistically significant at P <0.05.
Results
CD1c+ mDCs have an increased frequency and activated
phenotype in RA synovial fluid
mDCs were characterised by the expression of CD1c
and the absence of CD19 in MNC fractions of paired PB
and SF samples (n = 10) of RA patients (representative
dot plot; Figure 1A). The number of mDCs, determined
Table 2 Cytokines assessed in supernatants of cultured CD1c+ myeloid dendritic cells derived from PB and SF of
rheumatoid arthritis patients
PB (pg/ml) SF (pg/ml)
Proinflammatory cytokines
IL-1α 409 (150) 344 (343)
IL-1β 258 (65.5) 298 (280)
IL-1RA 2,561 (1,034) 2,769 (3,531)
IL-6 41.0 (13.3) 29.6 (22.6)
IL-6R 324 (100) 343 (199)
IL-18 149 (47.9) 180 (165)
Tumour necrosis factor alpha 99.1 (95.5) 170 (165)
Interferon alpha 153 (69.5) 157 (168)
Thymic stromal lymphopoeitin <LDL <LDL
T cell-differentiating and T cell-activating cytokines
IL-12p70 17.6 (11.1) 18.9 (18.5)
IL-23 444 (354) 420 (393)
IL-33 260 (101) 336 (391)
IL-13 857 (387) 1,054 (1,426)
IL-10 112 (49.9) 126 (63.1)
Macrophage migration inhibitory factor 1,872 (704) 2,948 (1,960)
IL-7 25.8 (6.9) 29.2 (29.7)
IL-9 3,087 (1,195) 3,280 (3,758)
IL-15 21.7 (8.7) 29.4 (27.3)
IL-21 5,114 (1,834) 6,343 (4,710)
IL-22 19.2 (6.1) 29.0 (27.3)
IL-25 1,140 (526) 1,239 (1,310)
Chemokines
IL-16 239 (101) 633 (581)†
CCL2/MCP1 29.7 (18.5) 24.6 (25.5)
CCL3/MIP1α 1,268 (1,847) 2,776 (3,954)
CCL5/RANTES <LDL <LDL
CCL17/TARC 1.2 (0.5) 26.4 (23.6)**
CCL19/MIP3β 28.4 (11.5) 57.5 (51.5)
CCL22/MDC 4,397 (1,627) 2,456 (1,023)*
CXCL9/MIG 23.9 (16.1) 90.4 (67.9)**
CXCL10/IP-10 54.0 (70.3) 247 (310)*
Growth factors/others
Oncostatin M 28.0 (21.7) 23.5 (17.8)
Fibroblast growth factor basic 4,046 (1,647) 4,777 (5,559)
Nerve growth factor 63.0 (23.2) 76.7 (90.2)
Hepatocyte growth factor 118 (46.8) 151 (143)
Granulocyte–macrophage colony-stimulating factor 650 (283) 827 (859)
Macrophage colony-stimulating factor 484 (188) 571 (730)
Vascular endothelial growth factor 191 (110) 202 (125)
IL-11 49.6 (20.1) 53.6 (63.9)
Soluble intracellular adhesion molecule-1 34,067 (139,11) 37,260 (46,225)
Osteopontin 11,192 (4,471) 15,528 (10,471)
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Table 2 Cytokines assessed in supernatants of cultured CD1c+ myeloid dendritic cells derived from PB and SF of
rheumatoid arthritis patients (Continued)
Matrix metalloproteinase-8 2,237 (1,594) 2,742 (4,634)
Tissue inhibitor of metalloproteinases-1 2,689 (1,126) 2,455 (2,169)
Cathepsin B 4,204 (1,554) 6,283 (4,948)
Cathepsin L 215 (101) 594 (731)
Cathepsin S 133 (55.3) 159 (130)
Data presented as mean (standard deviation). IP-10, interferon-gamma inducible protein-10; LDL, lower detection limit; MCP-1, monocyte chemotactic protein-1;
MDC, macrophage-derived chemokine; MIG, monokine induced by interferon-gamma; MIP, macrophage inflammatory protein; PB, peripheral blood; RANTES, regulated
upon activation, normally T cell-expressed, and presumably secreted; SF, synovial fluid; TARC, thymus and activation-regulated chemokine; IL, interleukin. *P <0.05;
**P <0.01; †P = 0.10.
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in SF versus PB (mean ± standard error of the mean: 4.7 ±
1.5% vs. 0.6 ± 0.1%, respectively, P <0.01) as well as the
CD1c expression (MFI: 778 ± 97 vs. 372 ± 18, respectively,
P <0.01; Figure 1B). Cell surface markers on mDCs
derived from PB and SF of RA patients were also studied











Figure 1 CD1c+ myeloid dendritic cells are abundantly present in join
of antigen-presenting and costimulatory molecules. (A) Representative
myeloid dendritic cells (mDCs) and CD19+ cells in the peripheral blood (PB
numbers are increased in SF versus PB of RA patients (n = 10), and SF mDC
cell (MNC) population and mean fluorescent intensity (MFI) of CD1c expres
levels of antigen-presenting (human leukocyte antigen class II (HLA-II)) and
PB-derived mDCs (n = 3). Representative histograms of isotype control (ope
shown (MFI corrected for isotype fluorescence). Statistically significant diffecompared with those from PB expressed increased levels
of antigen-presenting molecules HLA class II and costi-
mulatory molecules CD80, CD86 and CD40 (representa-
tive histograms and MFI; Figure 1C). In addition to the
MFI, the percentage of SF mDCs expressing all these acti-
vation markers was also significantly increased compared
with PB mDCs (mean ± standard error of the mean %9
B
ts of rheumatoid arthritis patients and express increased levels
fluorescence-activated cell sorting (FACS) dot plot of CD1c-expressing
) and synovial fluid (SF) of a rheumatoid arthritis (RA) patient. (B) mDC
s express higher CD1c levels. Percentages (%) of the total mononuclear
sion are given. (C) mDCs derived from SF (n = 5) express enhanced
costimulatory molecules (CD80, CD86 and CD40) as compared with
n) and HLA-II, CD80, CD86 and CD40 (filled) expression and mean are
rences of *P <0.05 and **P <0.01.
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10% vs. 90 ± 3%, P <0.05; CD80, 4 ± 1% vs. 35 ± 10%,
P <0.05; CD86, 30 ± 7% vs. 63 ± 10%, P = 0.07; CD40,
0.2 ± 0% vs. 11 ± 3%, P <0.05).
Synovial fluid-derived CD1c+ mDCs from RA patients
secrete higher levels of specific cytokines compared with
peripheral blood mDCs
To study the functional properties of CD1c+ mDCs these
were isolated from PB MNCs and SF MNCs of RA pa-
tients (n = 6; representative dot plot, Figure 2A). A small
subset of CD1c+ mDCs has been described to express
CD14. Therefore, the percentage of CD14-expresssing
cells was assessed in CD19– MNC fractions and in isolated
CD1c+ cells. Only a small proportion of isolated CD1c+
cells expressed CD14, to a similar extent on CD1c+ mDCs
from PB and SF (n = 6; representative dot plots and mean
of paired PB and SF samples, Figure 2B).
Isolated CD1c+ cells were cultured for 20 hours in the
absence of stimuli and cytokine production was assessed









































Figure 2 CD1c+ myeloid dendritic cells from synovial fluid of rheuma
equal amounts of T cell-differentiating cytokines compared with thos
CD1c-expressing myeloid dendritic cells (mDCs) from peripheral blood (PB)
Representative dot plots of isotype (left), CD1c and CD14 expression on CD
PB and SF. A small percentage of mDCs from PB and SF (n = 6, paired sam
produced comparable levels of T-helper type (Th)-1, Th17 and Th2-differen
eral chemokines by SF mDCs was significantly upregulated and macrophag
with PB mDCs. Apart from the T cell-differentiating cytokines, only inflamm
differences of *P <0.05 and **P <0.01. IP-10, interferon-gamma inducible pr
and activation-regulated chemokine.12p70, IL-33, IL-1β, and IL-23 by mDCs from SF was not
significantly different from that of PB mDCs (all P >0.10;
Figure 2C). The secretion of the chemoattractive media-
tors IP-10, MIG, and TARC by SF mDCs was significantly
increased as compared with PB mDCs. Macrophage-
derived chemokine (MDC) production was significantly de-
creased by SF mDCs compared with PB mDCs (Figure 2D).
The production of the T cell attractant IL-16 by SF mDCs
was also elevated compared with PB mDCs, although this
did not reach statistical significance (P = 0.10; Figure 2D).
Inflammatory mediators that were under the detection
limit included RANTES (regulated upon activation, nor-
mally T cell-expressed, and presumably secreted) and
TSLP. All other mediators were secreted in equal
amounts by PB and SF mDCs (all P >0.10) (Table 2).
Intra-articular CD1c+ mDCs spontaneously induce
proliferation and cytokine secretion of autologous CD4+ T
cells in RA patients
Since mDCs from SF express increased levels of antigen-
presenting and costimulatory molecules and producedD
toid arthritis patients produce increased chemokine levels but
e from peripheral blood. (A) Representative dot plot of isolated
and synovial fluid (SF) of a rheumatoid arthritis (RA) patient. (B)
19– mononuclear cells (middle) and on isolated mDCs (right plot) from
ples) expresses CD14 (bar graph). (C) PB mDCs and SF mDCs (n = 6)
tiating cytokines interleukin (IL)-12, IL-23, IL-33. (D) Production of sev-
e-derived chemokine (MDC) significantly downregulated as compared
atory mediators that showed P ≤0.10 are shown. Statistically significant
otein-10; MIG, monokine induced by interferon-gamma; TARC, thymus
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well as increased levels of several inflammatory mediators
compared with mDCs from PB, we investigated the cap-
acity of PB-derived and SF-derived mDCs (n = 11 and n =
5, respectively) to activate autologous CD4+ T cells. CD4+
T cells co-cultured with SF mDCs showed a robust in-
crease in the induction of T cell proliferation compared
with PB mDCs (PB mDCs vs. SF mDCs:CD4 T cells (1:5),
1,503 ± 443 vs. 26,935 ± 7,543 counts/minute, P <0.01, re-
spectively; Figure 3A). Similar increased T cell activation
was observed when paired PB and SF mDCs from the
same donor were analysed (Figure 3B). The increase in the
induction of T cell proliferation was also associated with a
robust increase in the production of T cell cytokines, mea-
sured after restimulation with ionomycin/phorbol myris-
tate acetate. The production of IFNγ, IL-17 and IL-4 was
higher by SF mDCs versus PB mDCs (Figure 3C). To
test whether enhanced SF mDC-induced T cell activa-
tion was dependent on CD80/86 upregulation, CD80/86
costimulation was blocked by CTLA4-Ig. SF mDC-
induced T cell activation was completely blocked by
CTLA4-Ig (Figure 3D). To study whether the observed
differences between PB and SF mDCs were related to DC
maturation, as a control, we activated mDCs from PB withFigure 3 Intra-articular CD1c+ myeloid dendritic cells induce strong p
proinflammatory T cell cytokine production. (A) Inflammatory myeloid
autologous CD4+ T cells induced a strong spontaneous proliferation of CD
higher compared with mDCs from peripheral blood (PB; n = 11). (B) Paired
DCs/50,000 CD4+ T cells) showed a similar robust induction of autologous
strong production of proinflammatory cytokines (interferon gamma (IFNγ),
SF mDC-induced T cell proliferation was strongly dependent on CD80/86 c
Statistically significant differences of *P <0.05 and **P <0.01. CPM, counts pTSLP, previously shown to activate CD11c+ DCs and im-
plicated to play a proinflammatory role in RA [25,26].
TSLP-stimulated CD1c+ mDCs induced robust prolifera-
tion of autologous CD4+ T cells (unstimulated vs. TSLP-
stimulated mDCs:CD4 T cells (1:5), proliferation: from
1,000 ± 284 to 14,206 ± 2,426 counts/minute, P = 0.01,
respectively; n = 8 from PB of healthy controls).
Discussion
Hitherto, functional data on CD1c+ (BDCA-1+) mDCs
from RA patients are scarce. Here we demonstrate that
in RA patients naturally occurring CD1c+ mDCs are
present in higher frequency in SF and that these mDCs
have an activated phenotype and secrete increased levels
of a unique set of chemokines in comparison with mDCs
from PB. To our knowledge this is also the first study
that reports CD1c+ mDCs from SF of RA patients to
compellingly cause autologous T cell activation.
The majority of T cells present in SF of RA patients
were previously shown to express the CXC chemokine
receptor 3 (CXCR3), with a higher percentage of T cells
expressing CXCR3 in SF than in PB of RA patients
[27,28]. CXCR3 is mainly expressed on Th1 cells and
binds to its ligands CXCL10/IP-10 and CXCL9/MIGroliferation of CD4+ T cells associated with a strong increase in
dendritic cells (mDCs) from synovial fluid (SF) when added to
4+ T cells of rheumatoid arthritis (RA) patients (n = 5), significantly
analysis of mDCs from PB and SF from the same donors (n = 3, 10,000
T cell proliferation by SF mDCs. (C) mDCs from SF (n = 5) induced a
interleukin (IL)-17 and IL-4) compared with PB mDCs (n = 11). (D)
ostimulation as it was completely blocked in the presence of CTLA4-Ig.
er minute.
Moret et al. Arthritis Research & Therapy 2013, 15:R155 Page 8 of 10
http://arthritis-research.com/content/15/5/R155[29,30]. Elevated IP-10 and MIG levels are observed in
SF of RA patients compared with control SF from pa-
tients with osteoarthritis or traumatic joint injury [27],
and the present study shows that in vivo-activated CD1c+
mDCs from RA joints secrete high levels of IP-10 and
MIG. Furthermore, these mDCs secrete higher CCL17/
TARC levels compared with mDCs derived from PB.
TARC is a selective ligand for the CC chemokine recep-
tor 4 (CCR4) that is expressed by Th2 cells [29,30],
Th17 cells [31], and regulatory T cells [32], suggesting
that TARC contributes to attraction of these T cells into
the inflamed joints. Secretion of CCL22/MDC by SF
mDCs, another CCR4 ligand, was significantly lower
compared with that by PB mDCs. To what extent this
differential expression of CCR4 ligands influences the
chemotaxis of Th2, Th17 and regulatory T cells remains
to be demonstrated. Recently, it was demonstrated that
MDC levels in SF of RA patients are elevated compared
with osteoarthritis patients [33]. This may indicate that
other cell types could contribute to these enhanced
levels. Alternatively, the increased number of CD1c+
mDCs (~5-fold higher) in the joint compared with the
circulation of RA patients could contribute to elevated
intra-articular levels.
Apart from enhancing immune activation, DCs induced
under different conditions can also induce tolerance – by
increasing regulatory T cell activity, amongst other effects
[7,8]. Our data demonstrate that, in line with the en-
hanced expression of antigen-presenting and costimula-
tory molecules, SF-derived CD1c+ mDCs spontaneously
increased proliferation and Th1, Th17 and Th2 cell cyto-
kine production of autologous CD4+ T cells. Although we
did not measure regulatory T cell function, our data
demonstrate that mDCs from SF overrule suppression by
regulatory T cells and indicate that in vivo-activated CD1c+
mDCs from the joint have a strong capacity to induce
T cell expansion of infiltrating T cells without strongly
skewing the T cell balance. In line with this observation,
SF and PB mDCs secreted equal amounts of T cell-
differentiating cytokines. Since in RA joints a predo-
minance of Th1 and Th17 activity is observed, our data
suggest that in joints of RA patients further Th1 and
Th17 cell skewing is facilitated by local inflammatory
mediators (for example, IL-12) produced, for example,
by macrophages.
Recently, Frankenberger and colleagues showed via
gene expression analysis that CD14++CD16- as well as
CD16+ monocytes are both distinct from the CD1c+
blood DCs [34]. In the present study, CD14-expressing
cells that lacked CD1c were not present or were hardly
present in the isolated DC fractions (~0.5%); however, a
small percentage of the CD1c+ mDCs coexpressed
CD14, similar to previous reports for healthy controls
[20]. Our data demonstrate that activated mDCs from SFof RA patients show a robust homogenic upregulation of
HLA class II, CD80, CD86, CD40 and CD1c compared
with their circulating counterparts. This corresponds to
the robust T cell stimulatory capacity of these SF mDCs
and contradicts the assumption that a subpopulation of
CD14+ cells is responsible for the observed effects. In
addition, the percentages of CD14+CD1c+ mDCs between
PB and SF did not differ. These latter suggestions are in
line with the much lower T cell stimulatory capacity of
total CD14+ monocytes, either isolated from SF or from
PB (unpublished data). Recently, however, CD1c+ DCs ex-
pressing CD14 were suggested to represent human inflam-
matory DCs, present in inflammatory environments such
as ascites and RA joints, and potent inducers of Th17
cells [35]. Although individual data from RA SF cannot
be deduced from this latter study, CD14 seems to be
expressed at higher levels on inflammatory CD1c+
mDCs versus blood CD1c+ mDCs [35]. Differences in
this latter study and the present study, showing low and
comparable percentages of CD14+CD1c+ mDCs be-
tween PB and SF, might be related to the site of inflam-
mation studied (SF vs. ascites), but this remains to be
established.
Although a wide range of triggers might activate CD1c+
mDCs, the predominant triggers that activate these cells
in RA joints remain to be demonstrated [36]. Jongbloed
and colleagues investigated the capacity of SF mDCs to re-
spond to toll-like receptor-2 agonism. As compared with
healthy PB mDCs, mDCs from the joints of RA patients
produced equal amounts of tumour necrosis factor alpha
and increased amounts of IL-10 in response to activation
by Staphylococcus aureus peptidoglycan [22]. Based on
this study of toll-like receptor triggering, mDCs from the
joints of RA patients were suggested not to be activated
and to display a semi-mature phenotype [22]. In line with
these data the present study also failed to detect any ro-
bust differences between PB and SF mDCs in secretion of
cytokines (including IL-1, IL-6, tumour necrosis factor
alpha, IFNα) typically induced upon toll-like receptor-2 or
other toll-like receptor triggering. However, the present
data clearly reveal an activated status of SF mDCs and a
powerful stimulation of T cells by these SF mDCs, which
suggests that stimuli other than toll-like receptor ligands
contribute to the enhanced activity of these cells in vivo,
associated with a unique set of secreted chemokines.
Recently, increased levels of TSLP in SF of RA patients
versus osteoarthritis patients were documented [37,38].
TSLP strongly induced TARC production by mDCs
from PB and SF of RA patients [38]. Furthermore,
mDCs from the peripheral blood, activated by TSLP,
showed phenotypical and functional similarities with
mDCs derived from the joints of RA patients, suggest-
ing that TSLP might be an important trigger for mDC
activation in RA joints [38].
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There is clear evidence that multiple subsets of DCs exist,
which display specialised functions although the tissue
microenvironment and the stage of maturation can influ-
ence their phenotype and function. The present study sug-
gests that accumulating CD1c+ mDCs in the joints of RA
patients importantly contribute to inflammation by indu-
cing secretion of a unique set of T cell-attracting chemo-
kines and by spontaneously activating CD4+ T cells to
proliferate and secrete proinflammatory cytokines. The
identification of the factors that control the capacity of
mDCs to elicit Th1, Th17 and Th2 development in RA is
critical to envisage new approaches to manipulate the
immune system to the benefit of these patients.
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